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Autogenous Access
(n  213)
Frosthetic Access
(n  120)
HR (95% CI) p-value HR (95% CI) p-value
Demographics
Increasing age
(years) 1.01 (0.98–1.03) 0.634 1.00 (0.97–1.03) 0.853
African American
Pace 0.56 (0.29–1.09) 0.090 1.48 (0.60–3.67) 0.398
Smoking status
Current Ref Ref
Former 1.00 (0.55–1.83) 0.999 1.38 (0.61–3.04) 0.455
Never 1.02 (0.49–2.14) 0.949 1.18 (0.50–2.79) 0.714
Comorbidities
Diabetes 1.21 (0.74–1.98) 0.444 2.12 (1.01–4.44) 0.047
Hypertension 0.88 (0.55–1.40) 0.584 1.45 (0.69–3.05) 0.326
Previous access in same
arm 0.78 (0.48–1.25) 0.309 0.83 (0.43–1.63) 0.594
Angiotensin receptor
blocker 0.35 (0.15–0.79) 0.012 0.40 (0.17–0.94) 0.035
Beta blocker 0.49 (0.27–0.90) 0.021 1.27 (0.68–2.36) 0.457
Antiplatelet medication 0.75 (0.41–1.37) 0.348 1.02 (0.56–1.86) 0.953
ACE inhibitor 0.80 (0.50–1.27) 0.340 0.51 (0.24–1.06) 0.072
Anti-angina agent 1.05 (0.57–1.95) 0.878 0.65 (0.18–2.30) 0.503
Anticoagulant 0.49 (0.16–1.49) 0.209 N/A1
Calcium channel
blocker 0.77 (0.46–1.31) 0.338 0.63 (0.33–1.23) 0.178
Diuretic 0.74 (0.45–1.23) 0.247 1.48 (0.62–3.43) 0.380
”Statin” (HMG Co-A
reductase
inhibitor) 1.32 (0.77–2.25) 0.312 0.59 (0.27–1.25) 0.166
Anti-hypertensive,
other 1.00 (0.57–1.75) 0.998 1.09 (0.40–2.95) 0.871
Lipid-lowering agent,
other 1.88 (0.58–6.09) 0.294 N/A1
Adjusted Relative Hazard of Access Failure
1Excluded from model due to small sample size using medication (antico-
agulant, n 3; lipid-lowering agent, other, n  1)
Author Disclosures: R. Amdur: Nothing to disclose;
R. A. Macsata: Nothing to disclose; R. S. Maybury:
Nothing to disclose; A. N. Sidawy: Nothing to disclose.
PS174.
Migration, Fracture, and Rupture as Complications of
Endovascular Grafts in the Treatment of Arteriovenous
Fistula
Dennis Wright1, Jill Zink1, Mirnal Chaudry2, Robert Net-
zley1, Victor Erzurum1. 1Akron General Medical Center,
Akron, OH; 2Northeastern Ohio Universities College of
Medicine, Rootstown, OH
Objectives:Endovascular stent grafts are utilized in the
rescue of failing AV access. Reports claim the superiorty of
stent grafts and recommended these as a first line treat-
ment. We have observed a rise in the number of complica-
tions related to stent grafts in our patients.
Methods: We reviewed all patients who had endovas-
cular stent grafts placed for treatment of failing dialysis
access over the last 36 months. A series of 27 consecutively
placed stent grafts was reviewed for stent migration, frac-
ture, hemorrhage and rupture at the site of the stent grafts.
Hospital charts were reviewed to assess for indications,
hemodynamic stability, transfusion requirement, and
outcome.
Results: Of 27 stent grafts placed, 9 were for pseudo-
aneurysm (PS), 15 for stenosis (ST), and 3 for a combina- pion (PS/ST). Six patients (22%) presented with complica-
ions (Table 1) related to migration, fracture, or rupture.
our of the six patients were in the pseudoaneurysm treat-
ent group. In all cases migration or fracture of the stent
raft lead to pseudoaneurysm formation. Four patient’s
equired ligation of the fistula to treat the complication and
wo dialysis access sites were salvaged.
Conclusions: Stent grafing of AV fistulas is seen in
ncreasing numbers of patients. Significant life threatening
omplication can arise when fracture and migration of the
tent grafts occur. Herald bleed with a previously placed
tent graft may be a harbinger of future rupture. Rupture
ppears less likely when stent grafts are used to treat steno-
is; surgical revision in the case of pseudoaneurysm should
e considered for access preservation.
able I.
Presentation and outcomes of stent graft complications # of pts
resented with significant bleeding episode 5
equired emergent/urgent operation 5
erald Bleed (At least 72 hrs prior to presentation) 4
ignificant hemodynamic instability (SBP 90) 3
equired blood transfusion ( 1 unit PRBC) 2
ardiopulmonary Arrest 1
ortality 0
uthor Disclosures: M. Chaudry: Nothing to disclose;
. Erzurum: Nothing to disclose; R. Netzley: Nothing to
isclose;D. Wright: Nothing to disclose; J. Zink: Nothing
o disclose.
S176.
hirty Day Outcomes following Brachiocephalic and
rachiobasilic Arteriovenous Fistula Formation: Na-
ional Benchmarks for Standard of Care
rateek K. Gupta1, Bala Natarajan1, Yeruva M. Reddy1,
imani Gupta1, Marcus Balters1, Jason M. Johanning2,
homas G. Lynch2, R. Armour Forse1, G. Matthew
ongo2, Jason N. MacTaggart2, Iraklis I. Pipinos2.
Creighton University, Omaha, NE; 2University of Ne-
raska Medical Center, Omaha, NE
Objectives: Dialysis access is one of the most fre-
uently performed vascular procedures, however, there is a
aucity of risk-adjusted, population-based data for postop-
rative outcomes following these procedures resulting in a
ack of national benchmarks for quality of care. The objec-
ive of this study was to report 30-day outcomes following
rachiocephalic and brachiobasilic arteriovenous fistula
AVF) formation.
Methods: Patients were identified from the American
ollege of Surgeons’ 2007-08 National Surgical Quality
mprovement Program (NSQIP) - a multicenter (more
han 180 hospitals), prospective database.
Results: In 2,037 patients, median age was 63 years
ith 53.7% being males and 52.1% Caucasians. Median
ody mass index was 28.3 kg/m2. Eighty nine percent
atients had hypertension, 47.0%were diabetics, and 78.7%
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minutes. Fifty-six percent patients received general anes-
thesia. Forty-one (2.0%) patients developed a wound infec-
tion, 51 (2.5%) patients developedmechanical failure of the
fistula requiring intervention, and 109 (5.4%) patients had
to return to the operating room. Thirty-day morbidity and
mortality rates were 11.7% and 1.1%, respectively. On
multivariate analysis, three preoperative predictors of mor-
tality were identified: age, dyspnea, and admission from
chronic care facility.
Conclusions: Morbidity and mortality rates following
AVF formation are low, making them relatively safe proce-
dures. We present outcomes from this large database to
define an average for the surgeon to compare their experi-
ence. These data will be used by third party interests, and
surgeons must understand it to place their outcomes into
the national norm.
Author Disclosures: M. Balters: Nothing to disclose; R.
Forse: Nothing to disclose; H. Gupta: Nothing to dis-
close; P. K. Gupta: Nothing to disclose; J. M. Johanning:
Nothing to disclose; G. Longo: Nothing to disclose; T. G.
Lynch: Nothing to disclose; J. N. MacTaggart: Nothing
to disclose; B. Natarajan: Nothing to disclose; I. I. Pipi-
nos: Nothing to disclose; Y. M. Reddy: Nothing to dis-
close.
PS178.
Expanded Use of the Hemodialysis Reliable Outflow
(HeRO) Vascular Access Device for Permanent Dialysis
Access in Patients with Total Central Venous Occlusion
Patrick J. O’Brien1, Charles Y. Kim2, Shawn M. Gage1,
Jeffrey H. Lawson1. 1Section of Vascular Surgery, Duke
University Medical Center, Durham, NC; 2Division of
Vascular & Interventional Radiology, Duke University
Medical Center, Durham, NC
Objectives: Central venous occlusion often results in
reliance on catheter-based dialysis access, which is a well-
established source of significant morbidity and mortality.
We retrospectively reviewed our experience with recanali-
zation of totally occluded central venous segments and
subsequent implantation of the HeRO vascular access de-
vice to provide permanent access in this catheter-dependent
population.
Methods: From September 2008 to July 2010, eight
catheter-dependent patients with total central venous occlu-
sion were identified. A catheter and guidewire system, using
both an upper extremity and femoral approach, was used to
traverse the central occlusion. Angioplasty was performed to
secure a tunneled catheter across the occluded segment for
future guidewire access andHeRO implantation.A temporary
tunneled catheter was used for hemodialysis access until the
HeRO graft was suitable for cannulation.
Results: HeRO implantation was successfully performed
in all eight patients. The mean age and length of time on
dialysis was 53.6 and 6.9 years, respectively. The recanalized uentral venous segment was the superior vena cava (n4),
rachiocephalic vein (n3), or subclavian vein (n1). One
atient died on postoperative day 11 of unrelated gastrointes-
inal bleeding. Mean follow-up for the remaining seven pa-
ients was 12.9 months (range 5-23 months). On average,
rafts were successfully accessed in 22.6 days, with patients
atheter-free at 29 days. Primary and secondary patency rates
t 6 months were 51% and 100%, respectively. One graft
equired revision secondary to local infection.
Conclusions: Recanalization of totally occluded cen-
ral venous segments followed by implantation of the
eRO device for permanent dialysis access is feasible, with
xcellent short-term patency in our current series. This
trategy may reduce the morbidity associated with chronic
ndwelling hemodialysis catheters, and extend anatomic
ptions previously abandoned in high-risk patients.
uthor Disclosures: S. M. Gage: Nothing to disclose;
. Y. Kim: Nothing to disclose; J. H. Lawson: Hemo-
phere, Inc.,Consulting fees or other remuneration (pay-
ent); P. J. O’Brien: Nothing to disclose.
S180.
actors Influencing Catheter Use for Hemodialysis in a
niversity-Associated Dialysis Center
aren Woo, Baron Thompson, Vincent Rowe. University
f Southern California, Los Angeles, CA
Objectives: To determine factors that influence use of
unneled catheters for hemodialysis in a single, university-
ssociated dialysis center.
Methods: A retrospective review was performed of
atients from a single university associated dialysis center
rom 2004-2009. Length of catheter use and number of
atheter placements per patient were analyzed. Demo-
raphics, co-morbidities and insurance status were also
ecorded.
Results: 403 patients were identified who had used a
atheter for hemodialysis on at least one occasion.
17 (54%) were males and 186 (46%) were females. The
ajority of the patients were Hispanic (76%). 78% of the
atients had diabetes. 168 (42%) of the patients had Med-
caid type insurance and 186 (46%) had Medicare. The
verall mean number of days using a catheter for hemodi-
lysis was 415. The overall mean number of catheter place-
ents was 2.1. Females had significantly more catheter use
ays than males (486 vs 354, P .04). Females also had
ignificantly more catheter placement events than males
2.3 vs 1.9, P 0.02). Insurance status did not affect number
f days using a catheter or number of catheter placements.
Conclusions: Catheter use for hemodialysis continues
o be significant in this predominantly Hispanic population
t a university-associated dialysis center. Female sex is a
ignificant predictor of catheter use. The reasons for this are
nclear. Further study is needed to determine the causes of
his discrepancy and identify strategies to decrease catheter
se in the hemodialysis population.
